The Tohoku University School of Medicine was established in 1915 as a part of Tohoku Imperial University, but it has roots extending all the way back to 1817, when the Sendai-han Medical School was founded. It has developed into a top-level organization for medical practice, education, and research. Prominent accomplishments include advances in electroencephalograms, the development of the Kasai procedure for congenital biliary atresia, and the introduction of mass examination for the early detection of cancer. Researchers at the School of Medicine also discovered moyamoya disease, the signaling mechanisms involved in protective responses (including those related to immune and oxidative stress), the neural networks that connect the major organs, and congenital diseases involving Ras and related signaling molecules. In cooperation with the University Hospital, the school is striving to translate its basic discoveries into innovations that will benefit patients.
Founded in 2002, the United Centers for Advanced Research and Translational Medicine (ART) http://www.art.med.tohoku.ac.jp/e/ is a part of the School of Medicine. Researchers at the center are vigorously pursuing basic research into the principles of life, clinical research based on associations between various organs, and translational research geared towards generating intellectual property. This three-fold mission is reflected in the three divisions of the center: the Division of Basic Medical Research, the Division of Translational Research, and the Division of Clinical Research.
Researchers at ART have forged many collaborations with scientists at other institutions, both in Japan and overseas. Within Tohoku University, the center has particularly strong connections with the Graduate School of Pharmaceutical Science, the Graduate School of Dentistry, the Graduate School of Biomedical Engineering, and the Institute of Development, Aging and Cancer.
Reflecting the current trend toward post-genomic research and recognizing the importance of going beyond genomic research, the center was reorganized in 2010 into core centers, each of which consists of a team of interdisciplinary researchers who share a common mission and research vectors. This core-center structure is intended to foster projects through a proactive, flexible organization rather than the vertical course-based approach typical of traditional research departments. ART currently has 14 core centers. While pursuing advanced multidisciplinary research based on their stated missions, each core center collaborates with the Clinical Research, Innovation and Education Center (CRIETO) in Tohoku University Hospital in areas ranging from basic medicine through translational research and clinical research. In this way, ART is seeking to strike an optimal balance between applied research, such as drug discovery and medical equipment research and development, and basic research, which will provide vital seeds for future science.
In addition, ART is actively seeking to promote the utilization of big data as well as provide a platform for collaboration between industry, academia, and government. Other priorities are to cultivate young researchers and bolster research infrastructure.
1 December 2017 - 30 November 2018
Principal institution: Tohoku University
Subject/journal group: All
The table to the right includes counts of all research outputs for Graduate School of Medicine / School of Medicine, Tohoku University published between 1 December 2017 - 30 November 2018 which are tracked by the Nature Index.
Hover over the donut graph to view the FC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.
Note: Articles may be assigned to more than one subject area.
Outputs by subject (FC)
|Angewandte Chemie International Edition||1||0.29|
|Earth & Environmental Sciences||2||0.31|
Highlight of the month
A metabolic gene variant promotes tumour growth
© Science Photo Library - MOREDUN ANIMAL HEALTH LTD/Getty
The variant of a metabolic gene that is responsible for tumour growth and proliferation has been identified. This promises to provide a new target for therapy.
A gene involved in breaking down the sugar glucose, PKM, is expressed in two variant forms, PKM1 and PKM2. Cancer cells and healthy cells have different ratios of the two variants.
To understand how these variants are involved in tumour growth, a team led by a Tohoku University Graduate School of Medicine researcher engineered mice to express each variant alone.
They found that mice expressing only PKM1 were more likely to develop cancer in response to a carcinogen than mice expressing only PKM2 cells. Further investigation revealed that neuroendocrine tumour cells had more PKM1 and thus a higher PKM1 to PKM2 ratio as well as increased cell proliferation.
These findings demonstrate the importance of PKM1 in tumour growth and highlight its potential as a therapeutic target for some types of cancer.
- Cancer Cell 33, 355–367 (2018). doi: 10.1016/j.ccell.2018.02.004
See more research highlights from Graduate School of Medicine / School of Medicine, Tohoku University
2 Apr 2019
Top articles by Altmetric score in current window
Generalizable representations of pain, cognitive control, and negative emotion in medial frontal cortex
Thermo-triggered release of CRISPR-Cas9 system by lipid-encapsulated gold nanoparticles for tumor therapy
Angewandte Chemie International Edition
Epigenetic modulation of Fgf21 in the perinatal mouse liver ameliorates diet-induced obesity in adulthood
Numerical information only is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.